Mark L. Bernstein

14.0k total citations · 1 hit paper
184 papers, 7.5k citations indexed

About

Mark L. Bernstein is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Neurology. According to data from OpenAlex, Mark L. Bernstein has authored 184 papers receiving a total of 7.5k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Molecular Biology, 47 papers in Pulmonary and Respiratory Medicine and 40 papers in Neurology. Recurrent topics in Mark L. Bernstein's work include Neuroblastoma Research and Treatments (38 papers), Sarcoma Diagnosis and Treatment (32 papers) and Cancer therapeutics and mechanisms (26 papers). Mark L. Bernstein is often cited by papers focused on Neuroblastoma Research and Treatments (38 papers), Sarcoma Diagnosis and Treatment (32 papers) and Cancer therapeutics and mechanisms (26 papers). Mark L. Bernstein collaborates with scholars based in United States, Canada and Switzerland. Mark L. Bernstein's co-authors include Mark Krailo, Susan M. Blaney, Holcombe E. Grier, Michael B. Harris, Allen M. Goorin, Mark C. Gebhardt, Neyssa Marina, John Moreland, Richard L. Momparler and Meenakshi Devidas and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Mark L. Bernstein

183 papers receiving 7.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group

2008 520 citations Paul A. Meyers, Cindy L. Schwartz et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Mark L. Bernstein

Since Specialization

Citations

This map shows the geographic impact of Mark L. Bernstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark L. Bernstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark L. Bernstein more than expected).

Fields of papers citing papers by Mark L. Bernstein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark L. Bernstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark L. Bernstein. The network helps show where Mark L. Bernstein may publish in the future.

Co-authorship network of co-authors of Mark L. Bernstein

This figure shows the co-authorship network connecting the top 25 collaborators of Mark L. Bernstein. A scholar is included among the top collaborators of Mark L. Bernstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark L. Bernstein. Mark L. Bernstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Outcome of patients with relapsed or progressive Ewing sarcoma enrolled on cooperative group phase 2 clinical trials: A report from the Children's Oncology Group 2021 ·Pediatric Blood & Cancer ·Anderson B. Collier, Mark Krailo, Ha Dang, Steven G. DuBois, Douglas S. Hawkins, Mark L. Bernstein, Lisa Bomgaars, Damon R. Reed, Richard Görlick, Katherine A. Janeway	13
2	Lack of trial participation and lack of centralization for young adults with osteosarcoma: Experience from the European and American Osteosarcoma Study, EURAMOS-1 2012 ·UCL Discovery (University College London) ·(unknown), Jennifer Hook, Gordana Jovic, Neyssa Marina, Peter Reichardt, Sigbjørn Smeland, Matthew R. Sydes, J. T. Whelan, Miriam Wilhelm, Katja Zils, Mark L. Bernstein	1
3	Phase II Trial of Trastuzumab in Combination With Cytotoxic Chemotherapy for Treatment of Metastatic Osteosarcoma With Human Epidermal Growth Factor Receptor 2 Overexpression: A Report From the Children's Oncology Group 2012 ·Journal of Clinical Oncology ·(unknown), Paul A. Meyers, Holcombe E. Grier, Mark L. Bernstein, Richard Görlick, Steven E. Lipshultz, Mark Krailo, Meenakshi Devidas, Donald A. Barkauskas, Gene P. Siegal, William S. Ferguson, G. Douglas Letson, Karen J. Marcus, Allen M. Goorin, (unknown), Neyssa Marina	184
4	Dose-Intensified Compared With Standard Chemotherapy for Nonmetastatic Ewing Sarcoma Family of Tumors: A Children's Oncology Group Study 2009 ·Journal of Clinical Oncology ·Linda Granowetter, Richard B. Womer, Meenakshi Devidas, Mark Krailo, Chenguang Wang, Mark L. Bernstein, Neyssa Marina, Patrick J. Leavey, Mark C. Gebhardt, John H. Healey, Robert C. Shamberger, Allen M. Goorin, James S. Miser, James S. Meyer, Carola A.S. Arndt, Scott L. Sailer, Karen J. Marcus, Elizabeth J. Perlman, Paul S. Dickman, Holcombe E. Grier	235
5	Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group breakdown → 2008 ·Journal of Clinical Oncology ·Paul A. Meyers, Cindy L. Schwartz, Mark Krailo, John H. Healey, Mark L. Bernstein, Donna L. Betcher, William S. Ferguson, Mark C. Gebhardt, Allen M. Goorin, Michael B. Harris, Eugenie S. Kleinerman, Michael P. Link, Helen Nadel, Michael L. Nieder, Gene P. Siegal, Michael A. Weiner, Robert J. Wells, Richard B. Womer, Holcombe E. Grier	520
6	Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children’s oncology group 2008 ·Cancer Chemotherapy and Pharmacology ·Patrick A. Thompson, Manish Gupta, Gary L. Rosner, Alexander Yu, Jeffrey S. Barrett, Lisa Bomgaars, Mark L. Bernstein, Susan M. Blaney, John Mondick	21
7	Inhibition of cytidine deaminase by zebularine enhances the antineoplastic action of 5-aza-2′-deoxycytidine 2008 ·Cancer Chemotherapy and Pharmacology ·Maryse Lemaire, Louise F. Momparler, Noël J.‐M. Raynal, Mark L. Bernstein, Richard L. Momparler	42
8	Complications of apheresis in children 2007 ·Transfusion ·Bruno Michon, Albert Moghrabi, Rochelle Winikoff, Stéphane Barrette, Mark L. Bernstein, Josette Champagne, Michéle David, Michel Duval, Heather Hume, Nancy Robitaille, (unknown), Martin Champagne	124
9	Phase 1 trial of O⁶‐benzylguanine and BCNU in children with CNS tumors: A Children's Oncology Group study 2007 ·Pediatric Blood & Cancer ·Denise M. Adams, Tianni Zhou, Stacey L. Berg, Mark L. Bernstein, Kathleen Neville, Susan M. Blaney	16
10	Local Control in Pelvic Ewing Sarcoma: Analysis From INT-0091—A Report From the Children's Oncology Group 2006 ·Journal of Clinical Oncology ·Torunn I. Yock, Mark Krailo, Christopher Fryer, Sarah S. Donaldson, James S. Miser, Zhengjia Chen, Mark L. Bernstein, Fran Laurie, Mark C. Gebhardt, Holcombe E. Grier, Nancy J. Tarbell	100
11	Health and Economic Benefits of Well-Designed Evaluations: Some Lessons From Evaluating Neuroblastoma Screening 2005 ·JNCI Journal of the National Cancer Institute ·(unknown), William G. Woods, Mark L. Bernstein, Leslie L. Robison, Mendel Tuchman, Bernard Lemieux	8
12	Osteopenia in Children Who Have Undergone Posterior Fossa or Craniospinal Irradiation for Brain Tumors 2004 ·Archives of Pediatrics and Adolescent Medicine ·Preetha Krishnamoorthy, Carolyn Freeman, Mark L. Bernstein, Sarah Lawrence, Celia Rodd	34
13	Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2′-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells 2003 ·Leukemia Research ·(unknown), Mark L. Bernstein, Louise F. Momparler, Richard L. Momparler	81
14	Biological aspects of neuroblastomas identified by mass screening in quebec 2001 ·Medical and Pediatric Oncology ·Garrett M. Brodeur, A. Thomas Look, Hiroyuki Shimada, (unknown), John M. Maris, H W Hann, Jean‐Marie Leclerc, Mark L. Bernstein, L Brisson, Josée Brossard, Bernard Lemieux, M Tuchman, William G. Woods	27
15	WR-2721 (amifostine) infusion in patients with Ewing's sarcoma receiving ifosfamide and cyclophosphamide with mesna: drug and thiol levels in plasma and blood cells, a Pediatric Oncology Group study 1999 ·Cancer Chemotherapy and Pharmacology ·Abdul‐Kader Souid, Robert C. Fahey, Ronald L. Dubowy, Gerald L. Newton, Mark L. Bernstein	21
16	Dyskeratosis congenita: An autosomal recessive variant 1999 ·American Journal of Medical Genetics ·Alison M. Elliott, Gail E. Graham, Mark L. Bernstein, Bruce Mazer, Ahmad S. Teebi	15
17	Idarubicin and Cytosine Arabinoside Reinduction Therapy for Children with Multiple Recurrent or Refractory Acute Lymphoblastic Leukemia: A Pediatric Oncology Group Study 1997 ·The American journal of pediatric hematology/oncology ·Mark L. Bernstein, Thomas C. Abshire, Brad H. Pollock, (unknown), Stuart Toledano, C. Philip Steuber, W. Paul Bowman, George R. Buchanan	16
18	A population-based study of the usefulness of screening for neuroblastoma 1996 ·The Lancet ·William G. Woods, Mendel Tuchman, Leslie L. Robison, Mark L. Bernstein, Jean-Marie Leclerc, L Brisson, Josée Brossard, Gerry Hill, Jonathan J. Shuster, Russell V. Luepker, Timothy D. Byrne, Sheila Weitzman, Greta R. Bunin, Bernard Lemieux	161
19	Screening for Neuroblastoma 1996 ·Cancer treatment and research ·Mark L. Bernstein, William G. Woods	4
20	Screening for Neuroblastoma in North America 1992 ·The Pediatric Infectious Disease Journal ·William G. Woods, Mendel Tuchman, Mark L. Bernstein, Jean‐Marie Leclerc, L Brisson, Thomas Look, Garrett M. Brodeur, Hiroyuki Shimada, Hie‐Won Hann, Leslie L. Robison, Jonathan J. Shuster, Bernard Lemieux	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact